ESPR's Q3 Earnings Lag Estimates, Revenues Rise Y/Y, Stock Down

Core Insights - Esperion Therapeutics (ESPR) reported a loss of $0.16 per share in Q3 2025, which was wider than the Zacks Consensus Estimate of a loss of $0.09 and compared to a loss of $0.15 per share in the same quarter last year [1][8] - The company generated total revenues of $87.3 million in Q3, marking a 69% year-over-year increase and surpassing the Zacks Consensus Estimate of $83 million [1][8] Financial Performance - Product revenues from the United States totaled $40.7 million in Q3, reflecting a 31% year-over-year increase but missing the Zacks Consensus Estimate of $42.9 million [7] - Collaboration revenues reached $46.7 million in Q3, up 128% year-over-year, driven by increased royalty sales and product sales to collaboration partners, beating the Zacks Consensus Estimate of $40.5 million [9] - Research and development expenses increased by 36% year-over-year to $14.1 million, while selling, general, and administrative expenses rose by 5% to $41.8 million due to higher legal and media costs [10] Future Outlook - Esperion expects operating expenses for 2025 to be in the range of $215-$235 million, including $15 million in non-cash stock compensation expenses, and aims for sustainable profitability by Q1 2026 [12] - The company has nominated ESP-2001, an allosteric ATP citrate lyase inhibitor, for preclinical development targeting primary sclerosing cholangitis, with plans to initiate IND-enabling studies and submit an IND application in 2026 [13] Recent Developments - Esperion reached a settlement with Dr. Reddy's regarding patents for Nexletol and Nexlizet, preventing the launch of generic versions in the U.S. before April 19, 2040, under certain conditions [14][15] - The company has two FDA-approved drugs, Nexletol and Nexlizet, for treating elevated LDL-C and cardiovascular risk reduction, marketed as Nilemdo and Nustendi in ex-U.S. markets [5][6] Stock Performance - Shares of Esperion fell by 15% on November 6, likely due to mixed Q3 results, despite a year-to-date increase of 13.7%, outperforming the industry average rise of 3.7% [2][4]